These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 7705494)

  • 61. Measles herd immunity. The association of attack rates with immunization rates in preschool children.
    Schlenker TL; Bain C; Baughman AL; Hadler SC
    JAMA; 1992 Feb; 267(6):823-6. PubMed ID: 1732654
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Measles epidemic in Romania, 1996-1998: assessment of vaccine effectiveness by case-control and cohort studies.
    Hennessey KA; Ion-Nedelcu N; Craciun MD; Toma F; Wattigney W; Strebel PM
    Am J Epidemiol; 1999 Dec; 150(11):1250-7. PubMed ID: 10588086
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The role of herd immunity in control of measles.
    Black FL
    Yale J Biol Med; 1982; 55(3-4):351-60. PubMed ID: 7180027
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Measles, mumps, and rubella vaccination.
    Hill A
    BMJ; 1992 Mar; 304(6829):779. PubMed ID: 1571700
    [No Abstract]   [Full Text] [Related]  

  • 66. Coverage of MMR vaccine.
    Begg N; Handford S
    Lancet; 1989 Dec 23-30; 2(8678-8679):1533. PubMed ID: 2574812
    [No Abstract]   [Full Text] [Related]  

  • 67. Measles vaccination policy.
    Williams BG; Cutts FT; Dye C
    Epidemiol Infect; 1995 Dec; 115(3):603-21. PubMed ID: 8557092
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Protecting the vaccinating population in the face of a measles epidemic: assessing the impact of adjusted vaccination schedules.
    van den Hof S; Wallinga J; Widdowson MA; Conyn-van Spaendonck MA
    Epidemiol Infect; 2002 Feb; 128(1):47-57. PubMed ID: 11895090
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Present anti-measles immunity in Jordan.
    Bdour S; Batayneh N
    Vaccine; 2001 Jul; 19(28-29):3865-9. PubMed ID: 11427259
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A mathematical model to measure the impact of the Measles Control Campaign on the potential for measles transmission in Australia.
    MacIntyre CR; Gay NJ; Gidding HF; Hull BP; Gilbert GL; McIntyre PB
    Int J Infect Dis; 2002 Dec; 6(4):277-82. PubMed ID: 12718821
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Estimating age-specific vaccine effectiveness using data from a large measles outbreak in Berlin, Germany, 2014/15: evidence for waning immunity.
    Bitzegeio J; Majowicz S; Matysiak-Klose D; Sagebiel D; Werber D
    Euro Surveill; 2019 Apr; 24(17):. PubMed ID: 31039834
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Age-related changes in the rate of disease transmission: implications for the design of vaccination programmes.
    Anderson RM; May RM
    J Hyg (Lond); 1985 Jun; 94(3):365-436. PubMed ID: 4008922
    [TBL] [Abstract][Full Text] [Related]  

  • 73. An ongoing large outbreak of measles in Merseyside, England, January to June 2012.
    Vivancos R; Keenan A; Farmer S; Atkinson J; Coffey E; Dardamissis E; Dillon J; Drew RJ; Fallon M; Huyton R; Jarvis R; Marsh G; Mason R; Shryane T; Stewart A; Ghebrehewet S
    Euro Surveill; 2012 Jul; 17(29):. PubMed ID: 22835470
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Modelling the incidence of measles in Canada: an assessment of the options for vaccination policy.
    Gay NJ; Pelletier L; Duclos P
    Vaccine; 1998 May; 16(8):794-801. PubMed ID: 9627936
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Measles vaccination coverage and seroprevalence of anti-measles antibody in south-east Islamic Republic of Iran.
    Izadi S; Mokhtari-Azad T; Zahraei SM
    East Mediterr Health J; 2015 Sep; 21(6):396-402. PubMed ID: 26369998
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immunity to measles in the Croatian population.
    Borcić B; Mazuran R; Kaić B
    Eur J Epidemiol; 2003; 18(11):1079-83. PubMed ID: 14620943
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The impact of Australia's measles control programme over the past decade.
    Gidding HF
    Epidemiol Infect; 2005 Feb; 133(1):99-105. PubMed ID: 15724716
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The declining antibody level of measles virus in China population, 2009-2015.
    Hu Y; Lu P; Deng X; Guo H; Zhou M
    BMC Public Health; 2018 Jul; 18(1):906. PubMed ID: 30041607
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Optimal vaccine schedules to maintain measles elimination with a two-dose routine policy.
    McKEE A; Shea K; Ferrari MJ
    Epidemiol Infect; 2017 Jan; 145(2):227-235. PubMed ID: 27760574
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination.
    Funk S; Knapp JK; Lebo E; Reef SE; Dabbagh AJ; Kretsinger K; Jit M; Edmunds WJ; Strebel PM
    BMC Med; 2019 Sep; 17(1):180. PubMed ID: 31551070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.